Arcus Biosciences, Inc. RCUS R2K

Healthcare · Biotechnology · United States

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Market & Price

Market Cap

$3.19B

Current Price

$25.34

High / Low (52W)

$26.62 / $7.95

Beta

0.87

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$4.17

Price to Book

6.07

P/S

13.50

EV/EBITDA

-6.37

Dividend Yield

Profitability & Returns

ROCE

-38.00%

ROE

-69.95%

ROA

-23.11%

Profit Margin

Op Margin

EPS (Latest Qtr)

$-1.02

EPS (TTM)

$-3.17

Balance Sheet & Liquidity

Debt/Equity

0.22

Quick Ratio

3.97

Current Ratio

4.04

Debt

$113.00M

Total Assets

$1.14B

Current Assets

$1.01B

Working Capital

$776.00M

Ownership

Promoter Holding

29.13%

Chg in Prom Hold

FII / Inst Holding

72.47%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

$2.48B

Total Revenue (TTM)

$236.00M

EBITDA

$-389.00M

Free Cash Flow

$-156.00M

Operating Cash Flow

$-488.00M

Shares Outstanding

125.77M

Gross Margin

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

30.16%

Profit 5Y

-10.74%

Revenue (YoY)

-39.30%

Earnings (YoY)

PROS

Compounding revenue at 30.2% over 5 years.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Earnings shrank at -10.7% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	RCUS Arcus Biosciences, Inc. R2K	25.34	-	$3.19B	-	-38.00%	-69.95%	30.16%	-10.74%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	1.75M	1.75M	1.75M	-	1.75M	1.75M	64.53M	-	9.46M	9.46M	9.46M	18.00M	27.00M	33.00M	25.00M	29.00M	32.00M	10.00M	11.00M	7.00M	-	28.00M	160.00M	26.00M	33.00M	17.00M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	150.00M	168.00M	168.00M	147.00M	151.00M
Operating Income	-7.30M	-9.66M	-23.13M	-	-13.33M	-15.90M	-12.14M	-	-18.77M	-29.16M	-23.25M	-	-28.40M	-45.38M	1.55M	-	-72.75M	-76.14M	-78.14M	-67.00M	-69.00M	-70.00M	-86.00M	-83.00M	-80.00M	-16.00M	-106.00M	-105.00M	-	-122.00M	-8.00M	-142.00M	-114.00M	-134.00M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-108.00M	4.00M	-130.00M	-101.00M	-123.00M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00M	2.00M	3.00M	2.00M	3.00M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-112.00M	0	-135.00M	-106.00M	-128.00M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Net Income	-7.20M	-9.55M	-23.12M	-13.21M	-12.95M	-13.53M	-10.81M	-12.29M	-17.67M	-28.09M	-22.35M	-16.60M	-27.75M	-45.07M	1.82M	-51.85M	-72.59M	-75.97M	-77.97M	-68.00M	-67.00M	-65.00M	-80.00M	-75.00M	-71.00M	-4.00M	-93.00M	-92.00M	-	-112.00M	0	-135.00M	-106.00M	-128.00M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-0.51	-	-	-	0.03	-	-	-	-1.11	-	-	-0.90	-1.09	-1.04	-0.94	-0.05	-1.02	-1.00	-	-1.14	0.00	-1.27	-0.89	-1.02
R&D Expense	5.80M	7.83M	21.43M	-	11.65M	13.70M	12.86M	-	15.55M	25.00M	17.24M	-	23.14M	35.69M	51.80M	-	66.39M	68.77M	71.25M	61.00M	70.00M	77.00M	81.00M	84.00M	82.00M	109.00M	115.00M	123.00M	-	122.00M	139.00M	141.00M	-	122.00M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	8.35M	15.00M	78.00M	-	112.00M	117.00M	258.00M	247.00M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	392.00M	457.00M	568.00M	633.00M
Operating Income	-18.18M	-53.44M	-54.86M	-88.71M	-124.00M	-	-280.00M	-340.00M	-310.00M	-386.00M
EBITDA	-	-	-	-	-	-	-258.00M	-291.00M	-268.00M	-335.00M
Interest Expense	-	-	-	-	-	-	2.00M	2.00M	4.00M	8.00M
Pretax Income	-	-	-	-	-	-	-266.00M	-301.00M	-282.00M	-353.00M
Tax Provision	-	-	-	-	-	-	1.00M	6.00M	1.00M	0
Net Income	-17.97M	-53.08M	-49.59M	-84.71M	-123.00M	-	-267.00M	-307.00M	-283.00M	-353.00M
Diluted EPS	-	-	-	-1.93	-2.24	0.71	-3.71	-4.15	-3.14	-
R&D Expense	14.25M	47.22M	49.65M	78.48M	159.00M	257.00M	288.00M	340.00M	448.00M	523.00M

Compounded Sales Growth

5 Years:	30.16%
1 Year:	-39.30%

Compounded Profit Growth

5 Years:	-10.74%
1 Year:	-

Stock Price Performance

1 Year:	+183.76%
6 Months:	+4.37%
3 Months:	+24.40%
1 Month:	+5.01%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	190.49M	274.93M	203.11M	772.29M	-	1.34B	1.09B	1.15B	1.14B
Current Assets	-	-	-	-	-	-	-	1.07B	831.00M	1.02B	1.01B
Cash & Equivalents	46.87M	65.16M	98.43M	71.06M	57.94M	173.41M	-	206.00M	127.00M	150.00M	222.00M
Inventory	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	39.00M	38.00M	20.00M	11.00M
Total Liabilities	-	-	36.62M	39.98M	39.27M	269.99M	-	688.00M	633.00M	665.00M	508.00M
Current Liabilities	-	-	12.73M	16.93M	22.71M	121.67M	-	193.00M	184.00M	226.00M	231.00M
Long Term Debt	-	-	-	-	-	-	-	-	-	48.00M	99.00M
Total Debt	-	-	-	-	-	-	-	3.00M	11.00M	60.00M	112.00M
Total Equity	-2.17M	-19.99M	-72.33M	234.94M	164.00M	502.00M	-	657.00M	462.00M	485.00M	631.00M
Shares Outstanding	-	-	-	-	-	-	-	72.90M	75.50M	92.20M	125.30M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-12.94M	-25.06M	-43.00M	-73.46M	111.00M	-	438.00M	-306.00M	-170.00M	-482.00M
Investing Cash Flow	-38.86M	-49.07M	-113.44M	59.21M	-434.00M	-	-413.00M	194.00M	-84.00M	66.00M
Financing Cash Flow	70.10M	107.40M	129.07M	1.12M	439.00M	-	33.00M	33.00M	277.00M	488.00M
Capital Expenditure	-4.10M	-5.51M	-3.74M	-1.93M	-3.00M	-	-6.00M	-24.00M	-6.00M	-2.00M
Free Cash Flow	-17.04M	-30.57M	-46.74M	-75.39M	108.00M	-	432.00M	-330.00M	-176.00M	-484.00M
Net Change in Cash	-	-	-	-	-	-	58.00M	-79.00M	23.00M	72.00M
Share Buybacks	-	-	0	94.00K	-	-	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-656.8%	-591.4%	-159.0%	-	-250.0%	-290.6%	-120.2%	-156.3%
Net Margin %	-	-	-593.7%	-564.7%	-157.7%	-	-238.4%	-262.4%	-109.7%	-142.9%
ROE %	89.9%	73.4%	-21.1%	-51.7%	-24.5%	-	-40.6%	-66.5%	-58.4%	-55.9%
ROCE %	-	-30.1%	-21.3%	-49.2%	-19.1%	-	-24.3%	-37.3%	-33.5%	-42.5%

Shareholding Pattern

Insiders

29.13%

Institutions

72.47%

Public Float

102.25%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Gilead Sciences Inc	24.99%	31.42M	$796.30M
2	Blackrock Inc.	12.11%	15.23M	$385.84M
3	Wellington Management Group, LLP	4.84%	6.09M	$154.31M
4	State Street Corporation	4.30%	5.41M	$137.16M
5	Suvretta Capital Management, LLC	4.00%	5.03M	$127.49M
6	Vanguard Portfolio Management LLC	3.40%	4.27M	$108.25M
7	Vanguard Capital Management LLC	3.07%	3.86M	$97.73M
8	Woodline Partners LP	3.00%	3.78M	$95.73M
9	Marshall Wace LLP	2.99%	3.76M	$95.31M
10	Siren, L.L.C.	2.39%	3.01M	$76.20M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RCUS

No recent headlines available.

RCUS · Healthcare